Castle Biosciences Revenue and Competitors
Estimated Revenue & Valuation
- Castle Biosciences's estimated annual revenue is currently $53M per year.
- Castle Biosciences received $5.1M in venture funding in June 2018.
- Castle Biosciences's estimated revenue per employee is $111,600
- Castle Biosciences's total funding is $354.3M.
Employee Data
- Castle Biosciences has 475 Employees.
- Castle Biosciences grew their employee count by 2% last year.
Castle Biosciences Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $1.7M | 11 | -8% | N/A | N/A |
#2 | $14.9M | 96 | -6% | N/A | N/A |
#3 | $15.2M | 98 | 3% | $1.8M | N/A |
#4 | $1.6M | 10 | 0% | N/A | N/A |
#5 | $3.4M | 22 | 0% | N/A | N/A |
#6 | $2.8M | 18 | 50% | N/A | N/A |
#7 | $7.4M | 48 | -2% | N/A | N/A |
#8 | $0.8M | 5 | 0% | N/A | N/A |
#9 | $1.6M | 10 | 0% | N/A | N/A |
#10 | $16.3M | 105 | 62% | N/A | N/A |
What Is Castle Biosciences?
Castle Biosciences, Inc. specializes in diagnostic tests for cancers. Founded in 2008, the company goal has been to help advance the care for cancers through objective testing. Our team works with outstanding members of the oncology community throughout the discovery, development and utilization of these tests. Currently, Castle Biosciences has tests to help doctors treat cutaneous melanoma, uveal melanoma, esophageal adenocarcinoma, mesothelioma and glioma. We have active research programs in rectal cancer and soft tissue sarcoma, and anticipate tests for these and other under-served cancers to be available in the near future Please visit us at www.castlebiosciences.com for more information on our company and products.
keywords:Biotechnology,Enterprise Software,Health It,Healthcare,Medical Diagnostics,Pharmaceuticals
$354.3M
Total Funding
475
Number of Employees
$53M
Revenue (est)
2%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Castle Biosciences's People
| Name | Title | Email/Phone |
|---|---|---|
1 | President, CEO and Founder | Reveal Email/Phone |
2 | Chief Commercial Officer | Reveal Email/Phone |
3 | Chief Operations Officer | Reveal Email/Phone |
4 | Associate Director, Accounting Services | Reveal Email/Phone |
5 | Associate Manager, Tradeshows | Reveal Email/Phone |
6 | Software Engineer II | Reveal Email/Phone |
7 | Regional Business Director | Reveal Email/Phone |
8 | Associate Director Clinical Research | Reveal Email/Phone |
9 | Medical Science Liaison, Diagnostic Gene Expression Profile (dGEP) | Reveal Email/Phone |
10 | Area Manager: TissueCypher | Reveal Email/Phone |
Castle Biosciences News
Castle Biosciences to Present Data at the 18th European Association of Dermato Oncology (EADO) Congress. Poster presentations to highlight...
Castle Biosciences (NASDAQ: CSTL) has recently received a number of price target changes and ratings updates: 4/14/2022 Castle Biosciences...
Castle Biosciences, which went public in 2019, makes tests that help guide treatment for certain cancers, including melanoma, squamous cell...
Castle Biosciences Announces Third Quarter 2021 Results Q3 2021 revenue grew by 54% over the prior year quarter to $23.5 million Q3 2021 total dermatology test report volume of 7,352 On track to achieve 2021 total revenue guidance of $89-93 million Conference call and webcast today at 4:30 p ...
LOS ANGELES (PRWEB) May 06, 2021 MedTech Breakthrough, an independent market intelligence organization that recognizes the top companies, technologies and products in the global health and medical technology market, today announced that Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer dia ...
Castle Biosciences Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2013-11-27 | $1.0M | Undisclosed | Article | |
| 2014-08-14 | $11.8M | Undisclosed | HealthQuest Capital | Article |
| 2015-04-15 | $6.0M | Undisclosed | Silicon Valley Bank | Article |
| 2015-07-28 | $11.7M | Undisclosed | Article | |
| 2016-03-15 | $14.0M | Undisclosed | Silicon Valley Bank | Article |
| 2017-05-10 | $20.0M | Undisclosed | Oxford Finance | Article |
| 2018-06-15 | $5.1M | Undisclosed | Article |